Davita Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while iShares 3 7 Year Treasury Bond ETF trades at $113.56 (market cap $16.72B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| DVA | IEI | |
|---|---|---|
Market Cap | $11.29B | $16.72B |
Volume | 582,204 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $120.72 |
52-Week Low | $103.87 | $113.17 |
Typical Hold Time | 113 Days | 43 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
IEI is trading at $113.38 with minimal daily movement (+0.04%). The technical picture shows strong bearish momentum across moving averages and oscillators, with key indicators like the ADX signaling strong downward trends. Recent bond market volatility and rising Treasury yields create a challenging environment for fixed-income related investments. The company has maintained consistent dividend payments, with recent distributions of $0.37-$0.38 per share.
The outlook remains cautious given the bearish technical signals and broader bond market pressures. While dividend consistency provides some stability, the lack of available fundamental metrics and negative technical momentum suggests limited near-term upside potential. Investors should monitor Treasury yield developments and company financial disclosures for clearer directional signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →